Adding new medications to improve treatment for children with T-cell blood cancers

Plain-English translation of NCT06390319 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether adding , , or to standard chemotherapy can help children with T-cell blood cancers respond better to treatment. Depending on the specific type of cancer your child has, one of these medications will be added to their chemotherapy plan. The goal is to improve how well the cancer responds to treatment and increase the chances of long-term survival.

T-cell acute lymphoblastic leukemia and related cancers can be harder to treat than other types of childhood leukemia. Researchers believe that adding one of these medications might help destroy cancer cells more effectively and give children better outcomes than standard chemotherapy alone.

Do you qualify?

You likely qualify if…

you are between 1 and 18 years old at the time of enrollment
you have been newly diagnosed with T-cell acute lymphoblastic leukemia, T-cell lymphoma, or mixed phenotype acute leukemia
you have had no prior chemotherapy (or only the first 3 days of treatment on the INITIALL protocol)
you have adequate liver and kidney function based on blood and urine tests
you are willing and able to take oral medications as prescribed

You likely don't qualify if…

you are pregnant or breastfeeding
you have HIV, hepatitis B, or hepatitis C
you have a condition that prevents you from taking medications by mouth
you are taking certain medications that interfere with the study drugs (such as rifampin, carbamazepine, phenytoin, or St. John's wort)
you have Grade 2 or higher nerve damage (for patients with T-cell lymphoma only)

What participation looks like

Your child will receive the new medication along with standard chemotherapy as part of a multi-phase treatment plan lasting about two years. Treatment is divided into three main phases: Induction (about 4 weeks), Early Post-Induction (several months of consolidation, high-dose , and intensification), and Maintenance (continued therapy to prevent relapse). Your child will have regular blood tests, spinal taps for chemotherapy delivery, and clinic visits to monitor response to treatment and manage side effects.

AI-generated summary from trial data · Jul 16, 2026 · Not medical advice

Adding new medications to improve treatment for children with T-cell blood cancers

What is this trial?

Do you qualify?

What participation looks like

Trial locations(4 sites)